Vical moves SARS vaccine at unprecedented speed into the clinic

15 Dec 2008

• By John Davis

The US firm Vical has shown that innovation is still alive and kicking in the industry – Phase I data on its potential SARS vaccine has been published only 19 months after the release of the genetic sequence of the coronavirus responsible for severe acute respiratory syndrome.

The results of the Phase I study of the vaccine, conducted at the US National Institutes of Health, were published...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

18 Jun 2025

• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

12 Jun 2025

• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

12 Jun 2025

• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.